<DOC>
	<DOC>NCT00454779</DOC>
	<brief_summary>This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent SCCHN.</brief_summary>
	<brief_title>PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologically confirmed metastatic and/or recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) determined to be incurable by surgery and/or radiation therapy. Measurable disease by CT scan Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 Age: 18 years or older Adequate hematologic, renal, metabolic, hepatic &amp; thyroid function Prior systemic treatment for metastatic and/or recurrent SCCHN CNS metastases, or nasopharyngeal carcinoma History of interstitial lung disease History of another primary cancer Any comorbid disease that would increase risk of toxicity Active infection requiring systemic treatment Prior antiEpidermal Growth Factor receptor (antiEGFr) antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SCCHNC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Recurrent</keyword>
</DOC>